Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Japan Vows Anew To Overcome Reluctance To Boost Generics Use

This article was originally published in PharmAsia News

Executive Summary

Despite slow adoption, the potential for massive shift in Japan’s branded-generics market is a draw for foreign firms as policymakers see increased usage as key to containing health costs.

You may also be interested in...



MHLW Reports Little Progress In Japan’s Generic Drug Use

Ministry of Health Labor and Welfare Minister Yoichiro Masuzoe and Treasury Minister Shoichi Nakagawa Dec. 18 announced a plan of reducing ¥220 billion in social insurance growth for fiscal year 2009, in which the real reduction will come from ¥23 billion as a result of generic drug use. However, a report released Dec. 15 by MHLW painted a discouraging picture of generic drug use in Japan, even amidst several pushes from the ministry to promote usage during the year.

Generic Drug Makers Preparing To Make Japanese Utilization Goal A Reality

TOKYO - The Japan Generic Medicines Association released survey results July 9 saying its 40 member companies are gearing up to manufacture considerably more generics in the next few years. Generic drug makers say they are meeting expectations set by the Ministry of Health, Labour and Welfare to raise Japan's generic drug use share for prescriptions from the current 17 percent to the government goal of 30 percent by fiscal year 2012

Generic Drug Use To Increase In Japan

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

SC080049

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel